MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

Search

Corvus Pharmaceuticals Inc

Abierto

7.59 -1.43

Resumen

Variación precio

24h

Actual

Mínimo

7.33

Máximo

7.91

Métricas clave

By Trading Economics

Ingresos

-23M

-8M

Margen de beneficios

-13,764.773

Empleados

31

EBITDA

-360K

-10M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+82.05% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

197M

530M

Apertura anterior

9.02

Cierre anterior

7.59

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 oct 2025, 23:25 UTC

Principales Movimientos del Mercado

Salesforce Rises on New FY30 Financial Targets

15 oct 2025, 18:52 UTC

Ganancias
Principales Movimientos del Mercado

Prologis Shares Gain on Raised Outlook, Data Center Growth

15 oct 2025, 18:30 UTC

Adquisiciones, fusiones, absorciones

Constellation Software to Buy U.K.'s Tecvia Holding

15 oct 2025, 17:19 UTC

Adquisiciones, fusiones, absorciones

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15 oct 2025, 17:11 UTC

Adquisiciones, fusiones, absorciones

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15 oct 2025, 23:48 UTC

Charlas de Mercado

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15 oct 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 oct 2025, 22:37 UTC

Charlas de Mercado

Economic Stars Are Aligning for RBA -- Market Talk

15 oct 2025, 21:44 UTC

Ganancias

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 oct 2025, 20:44 UTC

Adquisiciones, fusiones, absorciones

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15 oct 2025, 20:44 UTC

Adquisiciones, fusiones, absorciones

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15 oct 2025, 20:43 UTC

Adquisiciones, fusiones, absorciones

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15 oct 2025, 20:34 UTC

Ganancias

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15 oct 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15 oct 2025, 20:17 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15 oct 2025, 19:06 UTC

Ganancias

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15 oct 2025, 19:04 UTC

Charlas de Mercado

Oil Futures Post Back-to-Back Losses -- Market Talk

15 oct 2025, 18:46 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15 oct 2025, 18:23 UTC

Ganancias

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15 oct 2025, 17:37 UTC

Adquisiciones, fusiones, absorciones

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15 oct 2025, 17:34 UTC

Charlas de Mercado

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15 oct 2025, 16:57 UTC

Ganancias

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15 oct 2025, 16:51 UTC

Adquisiciones, fusiones, absorciones

EssilorLuxottica Doesn't Disclose Financial Details

15 oct 2025, 16:50 UTC

Adquisiciones, fusiones, absorciones

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15 oct 2025, 16:49 UTC

Adquisiciones, fusiones, absorciones

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15 oct 2025, 16:48 UTC

Adquisiciones, fusiones, absorciones

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15 oct 2025, 16:48 UTC

Adquisiciones, fusiones, absorciones

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15 oct 2025, 16:47 UTC

Adquisiciones, fusiones, absorciones

EssilorLuxottica Buys Ikerian

15 oct 2025, 16:34 UTC

Charlas de Mercado

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Comparación entre iguales

Cambio de precio

Corvus Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

82.05% repunte

Estimación a 12 Meses

Media 14 USD  82.05%

Máximo 16 USD

Mínimo 11 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Corvus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.165 / 3.5827Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat